To address this issue, an engineered T-cell product (named CARv3-TEAM-E) has been developed to target EGFRvIII through a second-generation CAR and secrete a T-cell-engaging antibody molecule (TEAM, a bispecific antibody) that can recognize wild-type EGFR in GBM cells and CD3 in T cells. The gene discussed is EGFR; the disease is glioblastoma.